{"id":"dacomitnib","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT06075615","NCT06321510"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"Dacomitnib is an irreversible tyrosine kinase inhibitor that blocks EGFR and HER2 signaling pathways. It is approved for non-small cell lung cancer with specific EGFR mutations. Its key differentiator is its irreversible binding mechanism, which provides sustained target inhibition compared to reversible inhibitors.","brandName":"dacomitnib","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis","explanation":"Dacomitnib works by targeting proteins called EGFR and HER2, which sit on the surface of cancer cells and receive growth signals. When these proteins are activated, they tell the cancer cell to grow and divide. Dacomitnib binds permanently to these proteins and locks them in an inactive state, preventing them from sending growth signals.\n\nWhat makes dacomitnib different from some other similar drugs is that its binding is irreversible. Think of it like putting a permanent lock on a switch rather than a temporary one. Once dacomitnib attaches to EGFR or HER2, it stays attached, which means the cancer cells can't escape its effects by producing new proteins or using alternate pathways as quickly.\n\nThis mechanism is particularly effective in lung cancers that have specific mutations in the EGFR gene. These mutations make cancer cells dependent on EGFR signaling for survival, so blocking it aggressively with an irreversible inhibitor can be especially powerful at stopping tumor growth.","oneSentence":"patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"dacomitnib","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Carcinoma, Non-Small-Cell Lung","phase":"discontinued","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06075615","phase":"discontinued","title":"A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to th","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":0,"indication":"Carcinoma, Non-Small-Cell Lung","completionDate":"2026-09","primaryEndpoint":"The purpose of this study is to learn about dacomitinib for the possible treatment of lung cancer which has spread to other parts of the body."},{"nctId":"NCT06321510","phase":"discontinued","title":"A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":29,"indication":"Lung Cancer","completionDate":"2025-12","primaryEndpoint":"The purpose of this study is to learn about dacomitinib for the possible treatment of lung cancer."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}